AstraZeneca, DRL invoved in Diabetes Drug Distribution Pact for Riax and Riax-M

AstraZeneca Pharma India and Dr Reddy’s Laboratories on Friday entered into a distribution agreement for two drugs – Riax and Riax-M – used for treatment of diabetes in India.

• Both Riax (saxagliptin) and Riax M (saxagliptin+Metformin) are trademarks of the AstraZeneca group.
• Dr Reddy’s Laboratories will be distributing the two drugs in India,

This partnership strengthens Dr Reddy’s diabetes franchise in India. It enables AstraZeneca to expand usage of this molecule through wider reach to physicians and benefiting more number of diabetic patients.

Saxagliptin (molecule) is a compound that plays a role in increasing release of insulin when glucose levels are elevated and reducing the levels of sugar produced by the liver.

AstraZeneca Pharma India already has two brands under the trademark Onglyza and Kombiglyze for saxagliptin and in fixed dose combination with metformin respectively, promoted and distributed in the Indian market.